MD Nexus

Lanadelumab (Takhzyro)

Indications

Hereditary Angioedema (see Angioedema)

Background

Lanadelumab was the First Monoclonal Antibody Approved (in 2018) for Prophylaxis Against Hereditary Angioedema (Type I or Type II) Attacks in Patients ≥12 y/o

Clinical Efficacy

HELP Placebo-Controlled Trial of Lanadelumab in Hereditary Angioedema (JAMA, 2018) [MEDLINE]: n = 125
- In Patients with Hereditary Angioedema (Type I or II), Lanadelumab (x 26 wks) Significantly Decreased the Attack Rate, as Compared to Placebo

Pharmacology

Human Monoclonal Antibody (Class IgG1 Kappa) Which Targets Plasma Kallikrein

Prevention of Angioedema in Patients with Hereditary Angioedema

Metabolism

xxxx

Administration

Subcutaneous (SQ)

Dose: 300 mg every q2-4wks

Dose Adjustment

Hepatic:
Renal:

Use in Pregnancy (see Pregnancy)

xxx

Use During Breast Feeding

xxxx

Adverse Effects

Other Adverse Effects

xxx
xxx
xxx

References

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial. JAMA. 2018 Nov 27;320(20):2108-2121. doi: 10.1001/jama.2018.16773 [MEDLINE]